Navigation Links
Webcast Alert: Isis Pharmaceuticals' First Quarter 2013 Financial Results Conference Call
Date:5/2/2013

CARLSBAD, Calif., May 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:What:Isis Pharmaceuticals' First Quarter 2013 Financial Results and Highlights Conference CallWhen:Tuesday, May 7, 2013 at 4:30 p.m. ET / 1:30 p.m. PTWhere:www.isispharm.com How:Live on the Internet.  Simply log onto our Web site listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENTThis press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
2. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
3. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
4. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013
5. Henry Schein To Webcast First Quarter 2013 Conference Call On Tuesday, May 7 At 10:00 a.m. ET
6. Thoratec Schedules First Quarter Conference Call, Webcast
7. Volcano Corporation Schedules First Quarter Conference Call, Webcast
8. Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013
9. Amgen Announces Webcast of 2013 First Quarter Financial Results
10. HeartWare Schedules First Quarter Conference Call And Webcast
11. Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has ... and Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Electrodes Market is poised to grow at a CAGR of around ... the market is witnessing include advancements in extracellular microelectrode arrays and ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... 8. Dezember 2016 Mederi Therapeutics Inc . hat die behördliche ... Behandlungsmethode für gastroösophageale Refluxerkrankung (GERD) – in China ... ... Live Stretta procedure performed and ... Director of Endoscopy at Wuhan Union Hospital ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ... “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health ... . , Results of the comparative usability study demonstrate that a dictation-based method ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation , ... and other pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger ... vice president of sales. , Litsinger joined Mirixa in 2008 after serving ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for ... In Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues ... implant and prosthetic market in the U.S. is projected to reach $6.4 billion in ...
(Date:12/8/2016)... ... , ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced ... program, at their world headquarters of Omni La Costa Resort & Spa in San ... seeking weight loss, personal development, a healthy lifestyle, or mental and physical healing. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
Breaking Medicine News(10 mins):